Form 8-K · Item 4.01 · Auditor change
Damora Therapeutics, Inc.: auditor change, EY Godkendt Revisionspartnerselskab to Ernst & Young LLP
Damora Therapeutics, Inc. reported in a Form 8-K filed April 20, 2026, that on April 17, 2026, EY Godkendt Revisionspartnerselskab was dismissed as its certifying accountant, and Ernst & Young LLP was engaged. The filing reports no disagreements with the former accountant.
In the filing's words
On April 17, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Damora Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed EY Godkendt Revisionspartnerselskab (“EY Denmark”) as the Company’s independent registered public accounting firm, effective immediately.
there were (i) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) with EY Denmark on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure
On April 17, 2026, the Audit Committee engaged Ernst & Young LLP (“EY US”) as the Company’s independent registered public accounting firm, effective immediately.
Verbatim from sec.gov, Item 4.01 (Changes in Registrant's Certifying Accountant). We quote the filing; we do not characterize it.
| Company | Damora Therapeutics, Inc. |
|---|---|
| Ticker | DMRA |
| Form and item | 8-K, Item 4.01 |
| Filed with the SEC | April 20, 2026 |
| What the filing states | dismissed, engaged |
| Former accountant | EY Godkendt Revisionspartnerselskab |
| New accountant | Ernst & Young LLP |
| Date of the change | April 17, 2026 |
| Disagreements | none reported |
| Auditor's letter | Exhibit 16 on sec.gov |
| Accession number | 0001193125-26-163909 |
| SEC CIK | 0001800315 |
Damora Therapeutics, Inc. reported under Form 8-K Item 4.01 (Changes in Registrant's Certifying Accountant), filed April 20, 2026. The filing's own words are quoted above.
Sources
More: all auditor changes · Something wrong? Send a correction with the primary source.